Strojan Primož, Corry June, Eisbruch Avraham, Vermorken Jan B, Mendenhall William M, Lee Anne W M, Haigentz Missak, Beitler Jonathan J, de Bree Remco, Takes Robert P, Paleri Vinidh, Kelly Charles G, Genden Eric M, Bradford Carol R, Harrison Louis B, Rinaldo Alessandra, Ferlito Alfio
Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia.
Head Neck. 2015 Jan;37(1):134-50. doi: 10.1002/hed.23542. Epub 2014 Jan 31.
Local and/or regional recurrence and metachronous primary tumor arising in a previously irradiated area are rather frequent events in patients with head and neck squamous cell carcinoma (HNSCC). Re-treatment is associated with an increased risk of serious toxicity and impaired quality of life (QOL) with an uncertain survival advantage.
We analyzed the literature on the efficacy and toxicity of photon/electron-based external beam reirradiation for previously irradiated patients with HNSCC of non-nasopharyngeal origin. Studies were grouped according to the radiotherapy technique used for reirradiation. Patient selection criteria, target volume identification method, tumor dose, fractionation schedule, systemic therapy administration, and toxicities were reviewed.
In addition to disease-related factors, current comorbidities and preexisting organ dysfunction must be considered when selecting patients for reirradiation. As morbidity from re-treatment may be considerable and differ depending on which mode of re-treatment is used, it is important to give patients information on potential morbidity outcomes so that an informed choice can be made within a shared decision-making context. With improved dose distribution and adequate imaging support, including positron emission tomography-CT, modern radiotherapy techniques may improve local control and reduce toxicity of reirradiation. A reirradiation dose of ≥60 Gy and a volume encompassing the gross tumor with up to a 5-mm margin are recommended. Concomitant administration of systemic therapeutics and reirradiation is likely to be of similar benefit as observed in large randomized studies of upfront therapy.
Reirradiation, administered either with or without concurrent systemic therapy, is feasible and tolerable in properly selected patients with recurrent or a new primary tumor in a previously irradiated area of the head and neck, offering a meaningful survival (in the range of 10% to 30% at 2 years). Whenever feasible, salvage surgery is the method of choice for curative intent; patients at high-risk for local recurrence should be advised that postoperative reirradiation is expected to increase locoregional control at the expense of higher toxicity and without survival advantage compared to salvage surgery without reirradiation. © 2014 Wiley Periodicals, Inc. Head Neck 37: 134-150, 2015.
头颈部鳞状细胞癌(HNSCC)患者中,局部和/或区域复发以及在先前放疗区域出现的异时性原发肿瘤是较为常见的情况。再次治疗会增加严重毒性风险,并损害生活质量(QOL),而生存优势并不确定。
我们分析了有关基于光子/电子的外照射再程放疗对先前接受过放疗的非鼻咽源性HNSCC患者的疗效和毒性的文献。研究根据再程放疗所采用的放射治疗技术进行分组。对患者选择标准、靶区体积确定方法、肿瘤剂量、分割方案、全身治疗的应用以及毒性反应进行了综述。
在选择再程放疗患者时,除了疾病相关因素外,还必须考虑当前的合并症和已存在的器官功能障碍。由于再次治疗的发病率可能相当高,并且因所采用的再治疗模式不同而有所差异,因此向患者告知潜在的发病结果非常重要,以便在共同决策的背景下做出明智的选择。随着剂量分布的改善和包括正电子发射断层扫描-CT在内的充分影像学支持,现代放疗技术可能会提高局部控制率并降低再程放疗的毒性。建议再程放疗剂量≥60 Gy,靶区体积应包括大体肿瘤并外放5 mm边界。全身治疗与再程放疗联合应用可能与大型 upfront 治疗随机研究中观察到的益处相似。
对于先前接受过头颈部放疗区域出现复发或新发原发肿瘤的患者,无论是否联合全身治疗,再程放疗在经过适当选择的患者中是可行且可耐受的,可提供有意义的生存(2年生存率在10%至30%之间)。只要可行,挽救性手术是根治性治疗的首选方法;对于局部复发高危患者,应告知其术后再程放疗预计会增加局部区域控制率,但会以更高的毒性为代价,且与未进行再程放疗的挽救性手术相比并无生存优势。© 2014 Wiley Periodicals, Inc. Head Neck 37: 134 - 150, 2015.